Regenerative Medicines: Bone and Joint Applications
Report Highlights
The U.S. market for regenerative medicine products used in bone and joint applications is expected to grow at a compound annual growth rate (CAGR) of 6.8% from $2.9 billion in 2015 to nearly $4.1 billion in 2020.
Report Includes
- An overview of the market for regenerative medicines in bone and joint applications, whose key objectives are the utilization of living cells to repair or replace body tissue damaged by injury, disease, or the aging process.
- Analyses of market trends, with data from 2014, estimates for 2015, and projections of CAGRs through 2020.
- Coverage of other regenerative applications, such as dental, neurologic, organ regeneration, cardiovascular, urologic, diabetes, and wound care, as well as stem cell research.
- Identification of market drivers, including an increase in diseases and disorders that will benefit from these products, primarily arthritis, osteoporosis, and various types of bone and joint trauma (e.g., hip fractures, knee injuries); increasing use of nonautograft products by physicians; and innovative devices that incorporate bone- and cartilage-growth-stimulating agents in a regenerative appliance.
- Descriptions of products, such as bone and cartilage grafting and regenerative products derived from autologous, allogeneic, and synthetic sources, as well as electrical stimulators for bone growth and regenerative cartilage products.
STUDY SCOPE AND FORMAT
The U.S. has been the main regenerative medicine market in terms of R&D innovation, patents and product sales often accounting for as much as half of the market depending on the product niche; hence, the scope of the study is mainly the U.S., although worldwide developments are discussed and measurements provided where relevant. The Overview section provides a background of the demographics underlying the market for bone and joint products, a definition of regenerative medicine and the technologies involved, and a discussion of regenerative products in development for applications other than bones and joints. Various application sections describe the leading bone and joint diseases and disorders applicable to regenerative technologies, including incidence and current methods of treatment.
The section on Products provides extensive descriptions and analyses (e.g., comparative analysis) of regenerative products used to treat bone and joint disorders, as well as a discussion of products in development.
The section on FDA clinical trials and newly approved products provides a discussion of regulatory issues affecting regenerative medicine products.
An extensive Company Profiles section provides estimates for the revenues of the leading companies and a concise description of leading and emerging companies in the area of regenerative products for bones and joints, including product introductions, patents and overall business strategies.
ANALYST’S CREDENTIALS
Research analyst Kevin Gainer holds both B.A. and M.A. degrees in quantitative economic analysis, and has 25 years of economic and market research experience. He is the author of five published books; dozens of technical papers, analyses, and studies published in conference proceedings; and many unpublished reports within corporations. He has worked as a Research Editor and Project Analyst at BCC Research, and, over the last 25 years, has authored many BCC technology market research reports.
Report Highlights
The U.S. market for regenerative medicine products used in bone and joint applications was estimated to total $2.72 billion in 2012 and is projected to increase to $2.73 billion in 2013. The market should total nearly $3.9 billion by 2018 and have a five-year compound annual growth rate (CAGR) of 7.3%.
Report Includes
- An overview of the market for regenerative medicines in bone and joint applications, whose key objectives are the utilization of living cells to repair or replace body tissue damaged by injury, disease, or the aging process.
- Analyses of market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
- Coverage of other regenerative applications, such as dental, neurologic, organ regeneration, cardiovascular, urologic, diabetes, and wound care, as well as stem cell research.
- Identification of market drivers, including an increase in diseases and disorders that will benefit from these products, primarily arthritis, osteoporosis, and various types of bone and joint trauma (e.g., hip fractures, knee injuries); increasing use of nonautograft products by physicians; and innovative devices that incorporate bone- and cartilage-growth-stimulating agents in a regenerative appliance.
- Descriptions of products, such as bone and cartilage grafting and regenerative products derived from autologous, allogeneic, and synthetic sources, as well as electrical stimulators for bone growth and regenerative cartilage products.
Report Highlights
- Overall sales in the regenerative medicine productsmarket were worth $1.1 billion in 2007, and remained flat into 2009. By 2014, sales are projected to increase to nearly $1.8 billion, for a 5-year compound annual growth rate (CAGR) of 8.6%.
- The largest segment in the market, bone replacement/grafting, was valued at $714 million in 2007. This also has increased only slightly into 2009 but is projected to reach $979 million in 2014, for a 5-year CAGR of 6.3%.
- Sales in the bone growth stimulators product segment were worth $321 million in 2007, and were to increase slightly into 2009. By 2014, however, they are projected to increase to $578 million, for a 5-year CAGR of 11.9%.
Report Highlights
-
The total U.S. market for bone and joint applications of regenerative medicine is projected to rise at an average annual growth rate of 8.5% to reach $1.4 billion in 2007.
-
Regenerative medicine refers to technologies that repair or replace diseased or defective tissues or organs. The main types of regenerative medicine utilize products naturally occurring in the body, such as genes and proteins (antibodies, growth factors, hormones); cells and tissues; embryonic stem cells, and biomaterials. At present, most regenerative medicines on the market fall into the first category and include protein-based drugs and therapies containing human cells. However, there are a few products based on tissue engineering. This technology, which promises to be the most exciting and fastest growing sector of regenerative medicine in the near future, is the primary focus of this report. Tissue engineering technologies discussed include matrices and scaffolds, in vitro and in vivo technologies, and novel materials, which include those utilizing nanotechnology (atomic-scale engineering) of inorganic substances that meld with human tissues.